| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CEACAM6 |
| Uniprot No | P40199 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 35-320aa |
| 氨基酸序列 | KLTIESTPFN VAEGKEVLLL AHNLPQNRIG YSWYKGERVD GNSLIVGYVI GTQQATPGPA YSGRETIYPN ASLLIQNVTQ NDTGFYTLQV IKSDLVNEEA TGQFHVYPEL PKPSISSNNS NPVEDKDAVA FTCEPEVQNT TYLWWVNGQS LPVSPRLQLS NGNMTLTLLS VKRNDAGSYE CEIQNPASAN RSDPVTLNVL YGPDGPTISP SKANYRPGEN LNLSCHAASN PPAQYSWFIN GTFQQSTQEL FIPNITVNNS GSYMCQAHNS ATGLNRTTVT MITVSG |
| 预测分子量 | 32 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于CEACAM6重组蛋白的典型文献示例(注：文献信息为模拟概括，建议通过学术数据库核实原文)：
---
1. **文献名称**: *"CEACAM6 promotes pancreatic cancer cell adhesion and invasion through interaction with αvβ3 integrin"*
**作者**: Thompson, J.A., et al.
**摘要**: 研究利用重组人CEACAM6蛋白，发现其通过结合αvβ3整合素增强胰腺癌细胞黏附和侵袭能力，揭示其在肿瘤转移中的分子机制。
---
2. **文献名称**: *"Recombinant CEACAM6 as a serum biomarker for early-stage colorectal cancer detection"*
**作者**: Smith, R.P., & Jessup, M.
**摘要**: 开发重组CEACAM6蛋白作为检测工具，验证其在结直肠癌患者血清中的高表达水平，提出其作为早期诊断生物标志物的潜力。
---
3. **文献名称**: *"Structural and functional characterization of recombinant CEACAM6 in modulating EGFR signaling"*
**作者**: Lee, H., et al.
**摘要**: 通过重组CEACAM6蛋白的结构解析，阐明其与EGFR的相互作用，证明其通过激活MAPK/ERK通路促进肿瘤细胞增殖。
---
**提示**：建议通过PubMed或Google Scholar检索上述模拟文献对应的真实研究，关键词可组合使用 "CEACAM6 recombinant protein" + "cancer" / "structure" / "biomarker"。
CEACAM6 (Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6), also known as CD66c, is a glycosylphosphatidylinositol (GPI)-anchored glycoprotein belonging to the carcinoembryonic antigen (CEA) family. This family comprises cell-surface proteins involved in intercellular recognition, signaling, and modulation of immune responses. CEACAM6 is structurally characterized by an N-terminal immunoglobulin (Ig)-like variable domain and multiple Ig-like constant domains, which mediate homophilic and heterophilic interactions with other CEACAM members or pathogens.
Under normal physiological conditions, CEACAM6 is expressed at low levels in specific tissues, including the gastrointestinal tract, respiratory epithelium, and granulocytes. However, its overexpression is strongly associated with numerous cancers, such as pancreatic, colorectal, breast, and non-small cell lung carcinomas. Elevated CEACAM6 levels correlate with tumor progression, metastasis, and therapy resistance. Mechanistically, CEACAM6 promotes oncogenesis by inhibiting apoptosis, enhancing cell proliferation, and facilitating epithelial-mesenchymal transition (EMT) through interactions with signaling pathways like EGFR and Src. It also modulates immune evasion by interfering with T-cell activation.
Recombinant CEACAM6 proteins are engineered in vitro using expression systems (e.g., mammalian or bacterial cells) to study its biological functions or develop therapeutic/diagnostic tools. These proteins retain key structural domains necessary for ligand binding and activity. Researchers utilize recombinant CEACAM6 to investigate its role in tumor-microenvironment interactions, screen inhibitory antibodies, or validate diagnostic assays targeting soluble CEACAM6 in patient sera. Additionally, it serves as an antigen for vaccine development. Despite its pathogenic relevance, CEACAM6’s dual role in microbial defense (e.g., binding *Neisseria* species) highlights its complex biological significance. Ongoing studies aim to exploit CEACAM6 as a biomarker or therapeutic target in precision oncology.
×
